Recursion Pharmaceuticals underperformed relative to the S&P 500 on August 22, 2025.
2 reports, 2 independent
Updated Aug 22
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Recursion Pharmaceuticals underperformed relative to the S&P 500 on August 22, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Recursion (United States)
company in Salt Lake City, United States
Related events
Coverage
Newest first; wire copies grouped- Simply Wall St.Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025 Recursion Pharmaceuticals reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experie
- ZacksRecursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged th